IRIS Accounts Production v25.1.3.33 01845674 Board of Directors 1.10.23 30.9.24 30.9.24 Medium entities true false true true false false true false These accounts have been prepared in accordance with the provisions applicable to companies subject to the medium-sized companies regime. Ordinary 1.00000 Ordinary (non-voting) 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh018456742023-09-30018456742024-09-30018456742023-10-012024-09-30018456742022-09-30018456742022-10-012023-09-30018456742023-09-3001845674ns15:EnglandWales2023-10-012024-09-3001845674ns14:PoundSterling2023-10-012024-09-3001845674ns10:Director12023-10-012024-09-3001845674ns10:PrivateLimitedCompanyLtd2023-10-012024-09-3001845674ns10:MediumEntities2023-10-012024-09-3001845674ns10:Audited2023-10-012024-09-3001845674ns10:Medium-sizedCompaniesRegimeForDirectorsReport2023-10-012024-09-3001845674ns10:Medium-sizedCompaniesRegimeForAccounts2023-10-012024-09-3001845674ns10:FullAccounts2023-10-012024-09-3001845674ns10:OrdinaryShareClass12023-10-012024-09-3001845674ns10:OrdinaryShareClass22023-10-012024-09-3001845674ns10:Director22023-10-012024-09-3001845674ns10:Director42023-10-012024-09-3001845674ns10:Director52023-10-012024-09-3001845674ns10:CompanySecretary12023-10-012024-09-3001845674ns10:RegisteredOffice2023-10-012024-09-3001845674ns10:Director32023-10-012024-09-3001845674ns5:RetainedEarningsAccumulatedLosses2023-09-3001845674ns5:RetainedEarningsAccumulatedLosses2022-09-3001845674ns5:RetainedEarningsAccumulatedLosses2024-09-3001845674ns5:RetainedEarningsAccumulatedLosses2023-09-3001845674ns5:CurrentFinancialInstruments2024-09-3001845674ns5:CurrentFinancialInstruments2023-09-3001845674ns5:Non-currentFinancialInstruments2024-09-3001845674ns5:Non-currentFinancialInstruments2023-09-3001845674ns5:ShareCapital2024-09-3001845674ns5:ShareCapital2023-09-3001845674ns5:LandBuildingsns5:OwnedOrFreeholdAssets2023-10-012024-09-3001845674ns5:LeaseholdImprovements2023-10-012024-09-3001845674ns5:PlantMachinery2023-10-012024-09-3001845674ns5:FurnitureFittings2023-10-012024-09-3001845674ns5:ComputerEquipment2023-10-012024-09-3001845674ns15:UnitedKingdom2023-10-012024-09-3001845674ns15:UnitedKingdom2022-10-012023-09-3001845674ns5:TotalGeographicSegmentsIncludingAnyUnallocatedAmount2023-10-012024-09-3001845674ns5:TotalGeographicSegmentsIncludingAnyUnallocatedAmount2022-10-012023-09-3001845674ns5:OwnedAssets2023-10-012024-09-3001845674ns5:OwnedAssets2022-10-012023-09-3001845674112023-10-012024-09-3001845674112022-10-012023-09-3001845674122023-10-012024-09-3001845674122022-10-012023-09-3001845674ns5:LandBuildings2023-09-3001845674ns5:LeaseholdImprovements2023-09-3001845674ns5:PlantMachinery2023-09-3001845674ns5:LandBuildings2023-10-012024-09-3001845674ns5:LandBuildings2024-09-3001845674ns5:LeaseholdImprovements2024-09-3001845674ns5:PlantMachinery2024-09-3001845674ns5:LandBuildings2023-09-3001845674ns5:LeaseholdImprovements2023-09-3001845674ns5:PlantMachinery2023-09-3001845674ns5:FurnitureFittings2023-09-3001845674ns5:ComputerEquipment2023-09-3001845674ns5:FurnitureFittings2024-09-3001845674ns5:ComputerEquipment2024-09-3001845674ns5:FurnitureFittings2023-09-3001845674ns5:ComputerEquipment2023-09-3001845674ns5:WithinOneYearns5:CurrentFinancialInstruments2024-09-3001845674ns5:WithinOneYearns5:CurrentFinancialInstruments2023-09-3001845674ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2024-09-3001845674ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2023-09-3001845674ns5:WithinOneYear2024-09-3001845674ns5:WithinOneYear2023-09-3001845674ns5:BetweenOneFiveYears2024-09-3001845674ns5:BetweenOneFiveYears2023-09-3001845674ns5:MoreThanFiveYears2024-09-3001845674ns5:MoreThanFiveYears2023-09-3001845674ns5:AllPeriods2024-09-3001845674ns5:AllPeriods2023-09-3001845674ns5:Secured2024-09-3001845674ns5:Secured2023-09-3001845674ns5:DeferredTaxation2023-09-3001845674ns5:DeferredTaxation2023-10-012024-09-3001845674ns5:DeferredTaxation2024-09-3001845674ns10:OrdinaryShareClass12024-09-3001845674ns10:OrdinaryShareClass22024-09-3001845674ns5:RetainedEarningsAccumulatedLosses2023-10-012024-09-30
REGISTERED NUMBER: 01845674 (England and Wales)














Strategic Report, Report of the Directors and

Financial Statements

for the Year Ended 30 September 2024

for

Ostomed Limited

Ostomed Limited (Registered number: 01845674)






Contents of the Financial Statements
for the Year Ended 30 September 2024




Page

Company Information 1

Strategic Report 2

Report of the Directors 3

Report of the Independent Auditors 5

Statement of Income and Retained Earnings 9

Balance Sheet 10

Cash Flow Statement 11

Notes to the Cash Flow Statement 12

Notes to the Financial Statements 13


Ostomed Limited

Company Information
for the Year Ended 30 September 2024







DIRECTORS: Mr R A Ainsworth
Mrs C L Ainsworth
Mr I Cartwright
Mr M Dale





SECRETARY: Mrs C L Ainsworth





REGISTERED OFFICE: Reedham House
31 King Street West
Manchester
Greater Manchester
M3 2PJ





REGISTERED NUMBER: 01845674 (England and Wales)





AUDITORS: Freedman Frankl & Taylor
Statutory Auditors
Chartered Accountants
Reedham House
31 King Street West
Manchester
M3 2PJ

Ostomed Limited (Registered number: 01845674)

Strategic Report
for the Year Ended 30 September 2024

The directors present their strategic report for the year ended 30 September 2024.

REVIEW OF BUSINESS
The results for the year and financial position as at 30 September 2024 of the company are as shown in the annexed financial statements.

The year to September 2024 showed the company continue to be profitable. However, despite gross profit margins improving from 15.54% to 16.56% year on year, net profit fell to £119,015 (2024: £143,129) as a result of wage inflation and some non-recurring legal fees.

The biggest risk to the business is the margin pressure within the industry, which has become more competitive over recent years, particularly due to some manufacturers' policy of limited distribution contracts with larger medical wholesalers. These are reviewed on an ongoing basis by the Directors and are a large area of focus, to maintain the health of the business.

The directors are confident that the business will remain profitable, despite the business not being re-awarded one of its larger distribution contracts in the year to September 2025. The directors are confident that some efficiency changes have been identified to retain profitability. Additionally, the business is in talks with new partners and are hopeful this will lead to new contracts in the near future.

Elsewhere, there are ongoing cost pressures and the directors are continuing to develop and improve relationships with all significant stakeholders and continue to seek opportunities to grow and retain the current levels of activity. A key focus also continues to be to maintain our levels of service both to customers and the end users of our products and services.

ON BEHALF OF THE BOARD:





Mr R A Ainsworth - Director


27 June 2025

Ostomed Limited (Registered number: 01845674)

Report of the Directors
for the Year Ended 30 September 2024

The directors present their report with the financial statements of the company for the year ended 30 September 2024.

PRINCIPAL ACTIVITY
The principal activity of the company in the year under review was that of distributors of medical supplies.

DIVIDENDS
No dividends will be distributed for the year ended 30 September 2024.

DIRECTORS
The directors shown below have held office during the whole of the period from 1 October 2023 to the date of this report.

Mr R A Ainsworth
Mrs C L Ainsworth
Mr I Cartwright
Mr M Dale

Other changes in directors holding office are as follows:

Mr S N Dawson - resigned 18 June 2024

STATEMENT OF DIRECTORS' RESPONSIBILITIES
The directors are responsible for preparing the Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

-select suitable accounting policies and then apply them consistently;
-make judgements and accounting estimates that are reasonable and prudent;
-prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Ostomed Limited (Registered number: 01845674)

Report of the Directors
for the Year Ended 30 September 2024


STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS
So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

ON BEHALF OF THE BOARD:




Mr R A Ainsworth - Director


27 June 2025

Report of the Independent Auditors to the Members of
Ostomed Limited

Opinion
We have audited the financial statements of Ostomed Limited (the 'company') for the year ended 30 September 2024 which comprise the Statement of Income and Retained Earnings, Balance Sheet, Cash Flow Statement and Notes to the Cash Flow Statement, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:
-give a true and fair view of the state of the company's affairs as at 30 September 2024 and of its profit for the year then ended;
-have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information
The directors are responsible for the other information. The other information comprises the information in the Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

Report of the Independent Auditors to the Members of
Ostomed Limited


Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors
As explained more fully in the Statement of Directors' Responsibilities set out on page three, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Report of the Independent Auditors to the Members of
Ostomed Limited


Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion.

Identifying and assessing potential risks to irregularities
In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:

Audit response to risks identified
- the nature of the industry and sector, control environment and business performance;
- results of enquiries of management about their own identification and assessment of the risks of irregularities;
- any matters we identified having obtained and reviewed the Company's documentation of their policies and
procedures relating to:

- identifying, evaluating and complying with laws and regulations and whether they were aware of any instances
of noncompliance;

- detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or
alleged fraud;
- the internal controls established to mitigate risks of fraud or non-compliance with laws and regulations;
- the matters discussed among the audit engagement team and involving other internal specialists including tax
regarding how and where fraud might occur in the financial statements and any potential indicators of fraud.

As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud. In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risks of management override.

We also obtained an understanding of the legal and regulatory frameworks that the Company operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements. The key laws and regulations we considered in this context included the UK Companies Act and local tax legislation.

As a result of performing the above, we did not identify any key audit matters related to the potential risk of fraud.

Our procedures to respond to risks identified included the following:
- reviewing the financial statement disclosures and testing to supporting documentation to assess compliance with
provisions of relevant laws and regulations described as having a direct effect on the financial statements;
- enquiring of management concerning actual and potential litigation and claims;
- performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of
material misstatement due to fraud;
- obtained an understanding of provisions and held discussions with management to understand the basis of
recognition or non-recognition of tax provisions; and

Report of the Independent Auditors to the Members of
Ostomed Limited

- in addressing the risks of fraud through management override of controls, testing the appropriateness of journal
entries and other adjustments; assessing whether the judgements made in making accounting estimates are indicative
of potential bias; and evaluating the business rationale of any significant transactions that are unusual or outside the
normal course of business.We also communicated relevant identified laws and regulations and potential fraud risks
to all engagement team members, and remained alert to any indications of fraud or noncompliance with laws and
regulations throughout the audit.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.




S Bacall BSc(HONS) BFP ACA (Senior Statutory Auditor)
for and on behalf of Freedman Frankl & Taylor
Statutory Auditors
Chartered Accountants
Reedham House
31 King Street West
Manchester
M3 2PJ

27 June 2025

Ostomed Limited (Registered number: 01845674)

Statement of Income and
Retained Earnings
for the Year Ended 30 September 2024

2024 2023
Notes £    £   

TURNOVER 3 22,225,180 22,555,112

Cost of sales (18,545,489 ) (19,050,033 )
GROSS PROFIT 3,679,691 3,505,079

Distribution costs (725,251 ) (713,947 )
Administrative expenses (2,833,021 ) (2,628,267 )
OPERATING PROFIT 5 121,419 162,865

Interest receivable and similar income 4,030 656
125,449 163,521

Interest payable and similar expenses 6 (6,434 ) (20,392 )
PROFIT BEFORE TAXATION 119,015 143,129

Tax on profit 7 (35,905 ) (36,259 )
PROFIT FOR THE FINANCIAL YEAR 83,110 106,870

Retained earnings at beginning of year 2,511,483 2,404,613

RETAINED EARNINGS AT END OF
YEAR

2,594,593

2,511,483

Ostomed Limited (Registered number: 01845674)

Balance Sheet
30 September 2024

2024 2023
Notes £    £   
FIXED ASSETS
Tangible assets 8 895,190 942,516

CURRENT ASSETS
Stocks 9 814,899 1,415,240
Debtors 10 4,090,307 2,980,750
Cash at bank and in hand 253,198 1,369,191
5,158,404 5,765,181
CREDITORS
Amounts falling due within one year 11 (3,398,059 ) (4,102,977 )
NET CURRENT ASSETS 1,760,345 1,662,204
TOTAL ASSETS LESS CURRENT
LIABILITIES

2,655,535

2,604,720

CREDITORS
Amounts falling due after more than one year 12 (35,168 ) (62,430 )

PROVISIONS FOR LIABILITIES 16 (11,846 ) (16,879 )
NET ASSETS 2,608,521 2,525,411

CAPITAL AND RESERVES
Called up share capital 17 13,928 13,928
Retained earnings 18 2,594,593 2,511,483
SHAREHOLDERS' FUNDS 2,608,521 2,525,411

The financial statements were approved by the Board of Directors and authorised for issue on 27 June 2025 and were signed on its behalf by:





Mr R A Ainsworth - Director


Ostomed Limited (Registered number: 01845674)

Cash Flow Statement
for the Year Ended 30 September 2024

2024 2023
Notes £    £   
Cash flows from operating activities
Cash generated from operations 1 (1,035,595 ) 861,310
Interest paid (6,434 ) (20,392 )
Tax paid (46,884 ) (5,393 )
Net cash from operating activities (1,088,913 ) 835,525

Cash flows from investing activities
Purchase of tangible fixed assets (3,848 ) (1,300 )
Interest received 4,030 656
Net cash from investing activities 182 (644 )

Cash flows from financing activities
Loan repayments in year (27,262 ) (52,258 )
Net cash from financing activities (27,262 ) (52,258 )

(Decrease)/increase in cash and cash equivalents (1,115,993 ) 782,623
Cash and cash equivalents at beginning of
year

2

1,369,191

586,568

Cash and cash equivalents at end of year 2 253,198 1,369,191

Ostomed Limited (Registered number: 01845674)

Notes to the Cash Flow Statement
for the Year Ended 30 September 2024

1. RECONCILIATION OF PROFIT BEFORE TAXATION TO CASH GENERATED FROM OPERATIONS

2024 2023
£    £   
Profit before taxation 119,015 143,129
Depreciation charges 51,176 71,965
Finance costs 6,434 20,392
Finance income (4,030 ) (656 )
172,595 234,830
Decrease/(increase) in stocks 600,341 (94,402 )
(Increase)/decrease in trade and other debtors (1,109,557 ) 80,782
(Decrease)/increase in trade and other creditors (698,974 ) 640,100
Cash generated from operations (1,035,595 ) 861,310

2. CASH AND CASH EQUIVALENTS

The amounts disclosed on the Cash Flow Statement in respect of cash and cash equivalents are in respect of these Balance Sheet amounts:

Year ended 30 September 2024
30.9.24 1.10.23
£    £   
Cash and cash equivalents 253,198 1,369,191
Year ended 30 September 2023
30.9.23 1.10.22
£    £   
Cash and cash equivalents 1,369,191 586,568


3. ANALYSIS OF CHANGES IN NET FUNDS

At 1.10.23 Cash flow At 30.9.24
£    £    £   
Net cash
Cash at bank and in hand 1,369,191 (1,115,993 ) 253,198
1,369,191 (1,115,993 ) 253,198
Debt
Debts falling due within 1 year (26,000 ) - (26,000 )
Debts falling due after 1 year (62,430 ) 27,262 (35,168 )
(88,430 ) 27,262 (61,168 )
Total 1,280,761 (1,088,731 ) 192,030

Ostomed Limited (Registered number: 01845674)

Notes to the Financial Statements
for the Year Ended 30 September 2024

1. STATUTORY INFORMATION

Ostomed Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Significant judgements and estimates
In applying the company's accounting policies, the directors are required to make judgements, estimates and assumptions in determining the carrying amounts of assets and liabilities. The directors' judgements, estimates and assumptions are based on the best and most reliable evidence available at the time when the decisions are made, and are based on historical experience and other factors that are considered to be applicable. Due to the inherent subjectivity involved in making such judgements, estimates and assumptions, the actual results and outcomes may differ.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revision to accounting estimates are recognised in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods, if the revision affects both current and future periods.

Key sources of estimation uncertainty
The key assumptions concerning the future, and other key sources of estimation uncertainty, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are disclosed below.

Assessing indicators of impairment
In assessing whether there have been any indicators of impairment assets, the directors have considered both external and internal sources of information such as market conditions and experience of recoverability. There have been no indicators of impairments identified during the current financial year.

Tangible fixed assets
Tangible fixed assets, are depreciated over their useful lives taking into account residual values, where appropriate. The actual lives of the assets and residual values are assessed annually and may vary depending on a number of factors. In re-assessing asset lives, factors such as technological innovation, product life cycles and maintenance programmes are taken into account. Residual value assessments consider issues such as future market conditions, the remaining life of the asset and projected disposal values.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Freehold property - 2% on cost
Improvements to property - 5% on reducing balance
Fixtures & fittings - 20% on cost
Plant and machinery - 15% on reducing balance
Computer equipment - 25% on cost

Tangible fixed assets are initially recorded at cost less accumulated depreciation and accumulated impairment losses.

Ostomed Limited (Registered number: 01845674)

Notes to the Financial Statements - continued
for the Year Ended 30 September 2024

2. ACCOUNTING POLICIES - continued

Stocks
Stocks are valued at the lower of cost and net realisable value on an average cost basis, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Comprehensive Income, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Going concern
The company's financial statements for the year have been prepared on a going concern basis as, after making appropriate enquiries, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future.

Operating lease commitments
Rentals paid under operating leases are charged to income as incurred.

3. TURNOVER

The turnover and profit before taxation are attributable to the one principal activity of the company.

An analysis of turnover by geographical market is given below:

2024 2023
£    £   
United Kingdom 22,225,180 22,555,112
22,225,180 22,555,112

Ostomed Limited (Registered number: 01845674)

Notes to the Financial Statements - continued
for the Year Ended 30 September 2024

4. EMPLOYEES AND DIRECTORS
2024 2023
£    £   
Wages and salaries 1,849,421 1,777,255
Social security costs 168,881 158,377
Other pension costs 38,376 33,799
2,056,678 1,969,431

The average number of employees during the year was as follows:
2024 2023

Selling & administration 67 69

2024 2023
£    £   
Directors' remuneration 194,672 219,898
Directors' pension contributions to money purchase schemes 5,818 5,818

The number of directors to whom retirement benefits were accruing was as follows:

Money purchase schemes 2 2

5. OPERATING PROFIT

The operating profit is stated after charging:

2024 2023
£    £   
Depreciation - owned assets 51,174 71,964
Auditors' remuneration 11,000 10,500
Operating leases - land & building 131,182 129,513
Operating leases - plant & machinery 276,117 241,028

6. INTEREST PAYABLE AND SIMILAR EXPENSES
2024 2023
£    £   
Bank interest 700 13,443
Loan interest 5,734 6,949
6,434 20,392

Ostomed Limited (Registered number: 01845674)

Notes to the Financial Statements - continued
for the Year Ended 30 September 2024

7. TAXATION

Analysis of the tax charge
The tax charge on the profit for the year was as follows:
2024 2023
£    £   
Current tax:
UK corporation tax 40,938 46,883

Deferred tax (5,033 ) (10,624 )
Tax on profit 35,905 36,259

Reconciliation of total tax charge included in profit and loss
The tax assessed for the year is higher than the standard rate of corporation tax in the UK. The difference is explained below:

2024 2023
£    £   
Profit before tax 119,015 143,129
Profit multiplied by the standard rate of corporation tax in the UK of 25%
(2023 - 25%)

29,754

35,782

Effects of:
Expenses not deductible for tax purposes 317 1,033
Depreciation in excess of capital allowances 5,834 5,817
Tax rate charge - (6,373 )
Total tax charge 35,905 36,259

Ostomed Limited (Registered number: 01845674)

Notes to the Financial Statements - continued
for the Year Ended 30 September 2024

8. TANGIBLE FIXED ASSETS
Improvements
Freehold to Fixtures
property property & fittings
£    £    £   
COST
At 1 October 2023 1,038,079 97,766 123,869
Additions - - 3,269
At 30 September 2024 1,038,079 97,766 127,138
DEPRECIATION
At 1 October 2023 235,960 46,326 119,344
Charge for year 20,762 2,571 3,338
At 30 September 2024 256,722 48,897 122,682
NET BOOK VALUE
At 30 September 2024 781,357 48,869 4,456
At 30 September 2023 802,119 51,440 4,525

Plant and Computer
machinery equipment Totals
£    £    £   
COST
At 1 October 2023 342,441 98,135 1,700,290
Additions - 579 3,848
At 30 September 2024 342,441 98,714 1,704,138
DEPRECIATION
At 1 October 2023 277,504 78,640 757,774
Charge for year 9,781 14,722 51,174
At 30 September 2024 287,285 93,362 808,948
NET BOOK VALUE
At 30 September 2024 55,156 5,352 895,190
At 30 September 2023 64,937 19,495 942,516

9. STOCKS
2024 2023
£    £   
Goods for resale 814,899 1,415,240

Ostomed Limited (Registered number: 01845674)

Notes to the Financial Statements - continued
for the Year Ended 30 September 2024

10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 3,976,443 2,894,590
Prepayments 113,864 86,160
4,090,307 2,980,750

11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Bank loans and overdrafts (see note 13) 26,000 26,000
Trade creditors 3,046,375 3,753,775
Corporation tax 40,938 46,884
Social security and other taxes 231,367 218,747
Accrued expenses 53,379 57,571
3,398,059 4,102,977

12. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2024 2023
£    £   
Bank loans (see note 13) 35,168 62,430

13. LOANS

An analysis of the maturity of loans is given below:

2024 2023
£    £   
Amounts falling due within one year or on demand:
Bank loans 26,000 26,000

Amounts falling due between two and five years:
Bank loans - 2-5 years 35,168 62,430

14. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
2024 2023
£    £   
Within one year 153,751 157,993
Between one and five years 502,885 544,664
In more than five years - 93,804
656,636 796,461

Ostomed Limited (Registered number: 01845674)

Notes to the Financial Statements - continued
for the Year Ended 30 September 2024

15. SECURED DEBTS

The following secured debts are included within creditors:

2024 2023
£    £   
Bank loans 61,168 88,430

16. PROVISIONS FOR LIABILITIES
2024 2023
£    £   
Deferred tax 11,846 16,879

Deferred
tax
£   
Balance at 1 October 2023 16,879
Credit to Statement of Comprehensive Income during year (5,033 )
Balance at 30 September 2024 11,846

Analysis of deferred tax balance

2024 2023
£ £
Accelerated capital allowances11,84616,879

17. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
10,000 Ordinary £1 10,000 10,000
3,928 Ordinary (non-voting) £1 3,928 3,928
13,928 13,928

18. RESERVES
Retained
earnings
£   

At 1 October 2023 2,511,483
Profit for the year 83,110
At 30 September 2024 2,594,593

Ostomed Limited (Registered number: 01845674)

Notes to the Financial Statements - continued
for the Year Ended 30 September 2024

19. ULTIMATE CONTROLLING PARTY

The company was controlled throughout the current and previous period by the director, Mr R A Ainsworth.